Story perspectives

Dexcom Unveils Smart Insulin Module, Shares Rise 2.6%

9/16/2025

39 3

Summary

Story summary

Dexcom plans to unveil its Smart Basal insulin titration module at the EASD Conference in Vienna, Austria.
The module aims to simplify basal insulin management and is currently under FDA and CE mark review.
Following the announcement, Dexcom's shares rose 2.6% but later stabilized at $76.47, a 0.3% increase from the previous close.
The company will present data indicating its continuous glucose monitor (CGM) is more effective than traditional methods in reducing acute diabetes events.
Year-to-date, Dexcom's stock is down 2.6% and trades 15.7% below its 52-week high.

1 of 1

Story summary

Dexcom plans to unveil its Smart Basal insulin titration module at the EASD Conference in Vienna, Austria.
The module aims to simplify basal insulin management and is currently under FDA and CE mark review.
Following the announcement, Dexcom's shares rose 2.6% but later stabilized at $76.47, a 0.3% increase from the previous close.
The company will present data indicating its continuous glucose monitor (CGM) is more effective than traditional methods in reducing acute diabetes events.
Year-to-date, Dexcom's stock is down 2.6% and trades 15.7% below its 52-week high.